Health and Healthcare
Pharmacopeia Scores Another Milestone (PCOP, GSK)
Published:
Pharmacopeia (Nasdaq: PCOP) has announced that it will receive a milestone payment of $5 million from GlaxoSmithKline (NYSE: GSK), bringing the total received to over $16 million in connection with its ongoing development and commercialization alliance.
The trigger for the additional milestone was Pharmacopeia’s completion of certain early discovery activities under its agreement with Glaxo. This alkso notes that Pharmacopeia is entitled to success-based milestone payments that can total up to $83 million per program for any drug development program pursued through the multi-program alliance. It can also receive up to double-digit royalties on the sales of any products commercialized by Glaxo under the alliance.
Before any pop here, Pharmacopeia had a mere $102 million market cap and had roughly $71.3 million in cash and equivalents on the books, and it also carried $67.3 million in total liabilities.
Jon C. Ogg
March 18, 2008
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
